A compounded version of Eli Lilly's injectable weight-loss and diabetes therapy tirzepatide, produced and sold by Apothecary ...
GSK's PD-1 inhibitor Jemperli has been cleared by the FDA as a pre-operative treatment for rectal cancer that can eliminate ...
Researchers in the US have developed an AI foundation model – trained on millions of facial images – that seems to be able to ...
AstraZeneca has launched a project with tech giant Oracle that will use AI and real-world data to improve clinical research, ...
A year after signing a first deal with Hansoh worth up to $1.45 billion, Roche has returned for another that could be more ...
Merck KGaA has reached a deal to acquire UK-based Silence Therapeutics in an all-cash, $1.3 billion deal that will boost its ...
In my experience, though, they are often used as a scapegoat for why social media doesn’t work in the pharma industry. I ...
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Cecilia Caetano, vice president, global medical ...
The much-anticipated pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs has arrived, with a deal that spans the current injectable products as well as ...
A drug for autoimmune disease Sjögren's syndrome, picked up by Novartis when it bought MorphoSys for $2.9 billion last year, has hit the target in a pair of phase 3 trials. Ianalumab (VAY736), a drug ...
Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results with a ...
Sanofi's consumer healthcare unit Opella could finally be on course to bring an over-the-counter PDE-5 inhibitor for erectile dysfunction to the US market, after the FDA relaxed its clinical hold on a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results